PMID- 28578922 OWN - NLM STAT- MEDLINE DCOM- 20181031 LR - 20220318 IS - 1573-2509 (Electronic) IS - 0920-9964 (Print) IS - 0920-9964 (Linking) VI - 192 DP - 2018 Feb TI - Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. PG - 357-363 LID - S0920-9964(17)30307-9 [pii] LID - 10.1016/j.schres.2017.05.032 [doi] AB - Depressed mood appears to be highly prevalent in clinical high risk (CHR) samples. However, many prior CHR studies utilize modest size samples and do not report on the specific impact of depression on CHR symptoms. The aim of the current paper is to investigate the prevalence of depressive disorders and the impact of lifetime depression on baseline clinical presentation and longitudinal outcomes in a large cohort of individuals meeting CHR criteria in the second phase of the North American Prodrome Longitudinal Study (NAPLS-2). Depression was assessed both categorically (via DSM-IV-TR diagnoses) and symptomatically (using a clinician-rated scale of depressive symptoms) within a sample of 764 individuals at CHR and 279 controls. Current and lifetime depressive disorders were highly prevalent (60%) in this sample. Depression diagnoses were associated with more pronounced negative and general symptoms; individuals with remitted depression had significantly less severe negative, disorganized, and general symptoms and better social and role functioning relative to those with current depression. Current mood disturbance, as measured by scores on a clinician-rated symptom scale, contributed beyond the impact of positive and negative symptoms to impairments in social functioning. Both symptomatic and diagnostic baseline depression was significantly associated with decreased likelihood of remission from CHR status; however depression did not differentially distinguish persistent CHR status from transition to psychosis at follow-up. These findings suggest that depressed mood may function as a marker of poor prognosis in CHR, yet effective treatment of depression within this population can yield improvements in symptoms and functioning. CI - Copyright (c) 2017 Elsevier B.V. All rights reserved. FAU - Kline, Emily R AU - Kline ER AD - Department of Psychiatry, Harvard Medical School at Beth, Israel Deaconess Medical Center, Boston, MA, United States. Electronic address: ekline@bidmc.harvard.edu. FAU - Seidman, Larry J AU - Seidman LJ AD - Department of Psychiatry, Harvard Medical School at Beth, Israel Deaconess Medical Center, Boston, MA, United States; Department of Psychiatry, Harvard Medical School at Massachusetts General Hospital, Boston, MA, United States. FAU - Cornblatt, Barbara A AU - Cornblatt BA AD - Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States. FAU - Woodberry, Kristen A AU - Woodberry KA AD - Department of Psychiatry, Harvard Medical School at Beth, Israel Deaconess Medical Center, Boston, MA, United States. FAU - Bryant, Caitlin AU - Bryant C AD - Department of Psychiatry, Harvard Medical School at Beth, Israel Deaconess Medical Center, Boston, MA, United States. FAU - Bearden, Carrie E AU - Bearden CE AD - Departments of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles, CA, United States. FAU - Cadenhead, Kristin S AU - Cadenhead KS AD - Department of Psychiatry, UCSD, San Diego, CA, United States. FAU - Cannon, Tyrone D AU - Cannon TD AD - Department of Psychology, Yale University, New Haven, CT, United States. FAU - Mathalon, Daniel H AU - Mathalon DH AD - Department of Psychiatry, UCSF and SFVA Medical Center, San Francisco, CA, United States. FAU - McGlashan, Thomas H AU - McGlashan TH AD - Department of Psychiatry, Yale University, New Haven, CT, United States. FAU - Perkins, Diana O AU - Perkins DO AD - Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States. FAU - Tsuang, Ming T AU - Tsuang MT AD - Department of Psychiatry, UCSD, San Diego, CA, United States. FAU - Walker, Elaine F AU - Walker EF AD - Departments of Psychology and Psychiatry, Emory University, Atlanta, GA, United States. FAU - Woods, Scott W AU - Woods SW AD - Department of Psychiatry, Yale University, New Haven, CT, United States. FAU - Addington, Jean AU - Addington J AD - Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. LA - eng GR - K23 MH102358/MH/NIMH NIH HHS/United States GR - U01 MH081902/MH/NIMH NIH HHS/United States GR - S10 RR019307/RR/NCRR NIH HHS/United States GR - P41 RR014075/RR/NCRR NIH HHS/United States GR - U01 MH081988/MH/NIMH NIH HHS/United States GR - M01 RR001032/RR/NCRR NIH HHS/United States GR - P50 MH066286/MH/NIMH NIH HHS/United States GR - K24 MH076191/MH/NIMH NIH HHS/United States GR - UL1 RR025758/RR/NCRR NIH HHS/United States GR - S10 RR023043/RR/NCRR NIH HHS/United States GR - U01 MH082022/MH/NIMH NIH HHS/United States GR - U01 MH081984/MH/NIMH NIH HHS/United States GR - R01 MH060720/MH/NIMH NIH HHS/United States GR - U01 MH081928/MH/NIMH NIH HHS/United States GR - S10 RR023401/RR/NCRR NIH HHS/United States GR - U01 MH081857/MH/NIMH NIH HHS/United States GR - U01 MH082004/MH/NIMH NIH HHS/United States GR - U01 MH081944/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20170601 PL - Netherlands TA - Schizophr Res JT - Schizophrenia research JID - 8804207 SB - IM MH - Adolescent MH - Adult MH - Child MH - Cohort Studies MH - Depression/diagnosis/*epidemiology/*psychology MH - Female MH - Humans MH - Male MH - North America MH - *Prodromal Symptoms MH - Psychiatric Status Rating Scales MH - Schizophrenia/complications/diagnosis/epidemiology MH - Schizophrenic Psychology MH - Social Adjustment MH - Statistics, Nonparametric MH - Young Adult PMC - PMC6342468 MID - NIHMS996394 OTO - NOTNLM OT - Mood OT - Prodrome OT - Psychosis OT - Remission OT - Schizophrenia COIS- Conflict of interest statement The authors have declared that there are no conflicts of interest in relation to the subject of this study. EDAT- 2017/06/06 06:00 MHDA- 2018/11/01 06:00 PMCR- 2019/02/01 CRDT- 2017/06/06 06:00 PHST- 2017/04/10 00:00 [received] PHST- 2017/05/24 00:00 [revised] PHST- 2017/05/25 00:00 [accepted] PHST- 2017/06/06 06:00 [pubmed] PHST- 2018/11/01 06:00 [medline] PHST- 2017/06/06 06:00 [entrez] PHST- 2019/02/01 00:00 [pmc-release] AID - S0920-9964(17)30307-9 [pii] AID - 10.1016/j.schres.2017.05.032 [doi] PST - ppublish SO - Schizophr Res. 2018 Feb;192:357-363. doi: 10.1016/j.schres.2017.05.032. Epub 2017 Jun 1.